Tuesday, 27 October 2026European Markets

EDP And NEOEN Have A High Dividend Yield And Return On Equity In The Utilities Sector.

Loading stream...

(vianews) - edp (edp.ls) is among this list of stock assets with the highest dividend rate and return on equity on the utilities sector.

financial asset price forward dividend yield return on equity
edp (edp.ls) €4.97 4% 10.6%
neoen (neoen.pa) €28.64 0.32% 2.78%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. edp (edp.ls)

4% forward dividend yield and 10.6% return on equity

edp - energias de portugal, s.a. engages in the generation, transmission, distribution, and supply of electricity in portugal, spain, france, poland, romania, italy, belgium, the united kingdom, greece, colombia, brazil, north america, and internationally. it operates through renewables, networks, and client solutions & energy management segments. the company primarily generates and sells electricity through hydro, ccgt, coal, wind, solar, nuclear, and cogeneration and waste sources. it has an installed capacity of 28 gw; and operates 380,788 kilometers of distribution network lines. the company is also involved in the supply of natural gas. in addition, it offers engineering, laboratory tests, professional training, and energy services, as well as property management services. the company's electricity and gas customers include domestic, industrial, commercial, agricultural, and others. edp - energias de portugal, s.a. was incorporated in 1976 and is headquartered in lisbon, portugal.

earnings per share

as for profitability, edp has a trailing twelve months eps of €0.21.

pe ratio

edp has a trailing twelve months price to earnings ratio of 23.66. meaning, the purchaser of the share is investing €23.66 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.6%.

revenue growth

year-on-year quarterly revenue growth grew by 45%, now sitting on 20.83b for the twelve trailing months.

more news about edp.

2. neoen (neoen.pa)

0.32% forward dividend yield and 2.78% return on equity

neoen s.a., an independent renewable energy production company, engages in the design, development, finance, construction project management, and operation of renewable energy power plants. the company operates solar, wind, and energy storage plants. it operates in argentina, australia, croatia, ecuador, united states, finland, france, ireland, italy, jamaica, mexico, mozambique, portugal, el salvador, sweden, and zambia. neoen s.a. was incorporated in 2008 and is headquartered in paris, france. neoen s.a. is a subsidiary of impala sas.

earnings per share

as for profitability, neoen has a trailing twelve months eps of €0.34.

pe ratio

neoen has a trailing twelve months price to earnings ratio of 84.24. meaning, the purchaser of the share is investing €84.24 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.78%.

more news about neoen.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com